Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.
The updated fair value estimate for Johnson & Johnson has shifted slightly from US$241.08 to US$241.71 per share, reflecting a modest price target change that investors are watching closely. That adjustment sits alongside a wave of recent analyst research in which many price targets are being lifted and fresh coverage is highlighting both the potential of newer therapies and the execution risks around the pipeline. Read on to see how to interpret these moving targets and what to watch as the narrative around Johnson & Johnson continues to evolve.
Several firms, including UBS, HSBC, Citi and JPMorgan, have lifted Johnson & Johnson price targets, signaling increased confidence in the company relative to their prior views.
HSBC highlights healthcare as potentially attractive in a period of uncertain macro conditions, citing Johnson & Johnson lower exposure to AI disruption risk as a possible appeal for some investors.
BofA and JPMorgan point to contributions from products such as Tremfya, Tecvayli, Inlexzo and Darzalex in recent research, which they factor into updated revenue assumptions and target prices.
TD Cowen, Morgan Stanley, Guggenheim and Stifel have all raised targets or reiterated positive stances since January 2026, reflecting a cluster of supportive views on execution and the product pipeline.
Some firms, including BofA and JPMorgan, keep Neutral ratings even as they lift price targets, which suggests they see a more balanced risk and reward profile at current levels.
References to execution risks around newer therapies and near to market assets indicate that timing, regulatory outcomes and competitive dynamics remain key watchpoints for anyone tracking Johnson & Johnson valuation story.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
NYSE:JNJ 1-Year Stock Price Chart
We’ve flagged 2 risks for Johnson & Johnson. See which could impact your investment.
The fair value estimate has adjusted from US$241.08 to US$241.71 per share.
The assumed long term revenue growth rate has moved from 6.16% to 6.24%.
The forecast net profit margin has shifted from 22.51% to 22.45%.
The assumed future P/E multiple has changed from 28.17x to 28.25x.
The discount rate remains essentially unchanged at 6.98%.
Story Continues
Narratives link a company story to a financial forecast and fair value, so you can see how product launches, deals and risks connect to the numbers. They are updated as new information comes through, which helps you keep the big picture in view.
Head over to the Simply Wall St Community and follow the Narrative on Johnson & Johnson to stay up to date on:
How growth in immunology and oncology, including next generation therapies, fits alongside the loss of exclusivity for STELARA.
What over US$55b of planned U.S. manufacturing, R&D and MedTech investment, plus acquisitions like Intra Cellular Therapies, could mean for future earnings mix.
Key risks around tariffs, ongoing talc litigation and pressure in orthopedics that could challenge margins even if sales grow in other areas.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include JNJ.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com